Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients
Percutaneous sclerotherapy is used to treat venous and lymphatic vascular malformations, which can cause significant discomfort and/or disfigurement. The purpose of this study is to describe the bleomycin sclerotherapy technique and to evaluate its clinical and radiological efficacy and safety. We r...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/6/1302 |
| _version_ | 1797540527466348544 |
|---|---|
| author | Franck Nevesny Olivier Chevallier Nicolas Falvo Kévin Guillen Alexandre Malakhia Julie Pellegrinelli Pierre-Olivier Comby Bertille Bonniaud Marco Midulla Romaric Loffroy |
| author_facet | Franck Nevesny Olivier Chevallier Nicolas Falvo Kévin Guillen Alexandre Malakhia Julie Pellegrinelli Pierre-Olivier Comby Bertille Bonniaud Marco Midulla Romaric Loffroy |
| author_sort | Franck Nevesny |
| collection | DOAJ |
| description | Percutaneous sclerotherapy is used to treat venous and lymphatic vascular malformations, which can cause significant discomfort and/or disfigurement. The purpose of this study is to describe the bleomycin sclerotherapy technique and to evaluate its clinical and radiological efficacy and safety. We retrospectively identified consecutive patients with venous malformations (VMs) and lymphatic malformations (LMs) who underwent bleomycin sclerotherapy in 2011–2020 at our institution. We collected the clinical and radiological success rates, complications and recurrences separately in the VM and LM groups. We identified 26 patients, 15 with VMs and 11 with LMs. The significant volume reductions obtained were 45% in the VM group and 76% in the LM group (<i>p</i> = 0.003 and <i>p</i> = 0.009, respectively). Significant reductions in discomfort/pain and in cosmetic disfigurement were obtained in both groups. An overall improvement was reported by 69% and 82% of patients in the VM and LM groups, respectively. No major complications occurred during the mean follow-up of 51 ± 34 months in the VM group and 29 ± 18 months in the LM group. A recurrence developed within 2 years in 23% of patients. Bleomycin is clinically and radiologically effective for the treatment of venous and lymphatic malformations, with a high level of patient safety. |
| first_indexed | 2024-03-10T13:01:28Z |
| format | Article |
| id | doaj.art-f64fcd4540e243f489a80d098689e720 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T13:01:28Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-f64fcd4540e243f489a80d098689e7202023-11-21T11:28:56ZengMDPI AGJournal of Clinical Medicine2077-03832021-03-01106130210.3390/jcm10061302Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 PatientsFranck Nevesny0Olivier Chevallier1Nicolas Falvo2Kévin Guillen3Alexandre Malakhia4Julie Pellegrinelli5Pierre-Olivier Comby6Bertille Bonniaud7Marco Midulla8Romaric Loffroy9Image-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceDepartment of Neuroradiology and Emergency Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceDepartment of Dermatology and Genetics of Developmental Anomalies, UMR Inserm 1231, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FranceImage-Guided Therapy Center, ImViA Laboratory-EA 7535, Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon, FrancePercutaneous sclerotherapy is used to treat venous and lymphatic vascular malformations, which can cause significant discomfort and/or disfigurement. The purpose of this study is to describe the bleomycin sclerotherapy technique and to evaluate its clinical and radiological efficacy and safety. We retrospectively identified consecutive patients with venous malformations (VMs) and lymphatic malformations (LMs) who underwent bleomycin sclerotherapy in 2011–2020 at our institution. We collected the clinical and radiological success rates, complications and recurrences separately in the VM and LM groups. We identified 26 patients, 15 with VMs and 11 with LMs. The significant volume reductions obtained were 45% in the VM group and 76% in the LM group (<i>p</i> = 0.003 and <i>p</i> = 0.009, respectively). Significant reductions in discomfort/pain and in cosmetic disfigurement were obtained in both groups. An overall improvement was reported by 69% and 82% of patients in the VM and LM groups, respectively. No major complications occurred during the mean follow-up of 51 ± 34 months in the VM group and 29 ± 18 months in the LM group. A recurrence developed within 2 years in 23% of patients. Bleomycin is clinically and radiologically effective for the treatment of venous and lymphatic malformations, with a high level of patient safety.https://www.mdpi.com/2077-0383/10/6/1302venous malformationslymphatic malformationspercutaneous sclerotherapybleomycinpatient-reported outcomes |
| spellingShingle | Franck Nevesny Olivier Chevallier Nicolas Falvo Kévin Guillen Alexandre Malakhia Julie Pellegrinelli Pierre-Olivier Comby Bertille Bonniaud Marco Midulla Romaric Loffroy Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients Journal of Clinical Medicine venous malformations lymphatic malformations percutaneous sclerotherapy bleomycin patient-reported outcomes |
| title | Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients |
| title_full | Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients |
| title_fullStr | Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients |
| title_full_unstemmed | Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients |
| title_short | Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients |
| title_sort | bleomycin for percutaneous sclerotherapy of venous and lymphatic malformations a retrospective study of safety efficacy and mid term outcomes in 26 patients |
| topic | venous malformations lymphatic malformations percutaneous sclerotherapy bleomycin patient-reported outcomes |
| url | https://www.mdpi.com/2077-0383/10/6/1302 |
| work_keys_str_mv | AT francknevesny bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT olivierchevallier bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT nicolasfalvo bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT kevinguillen bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT alexandremalakhia bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT juliepellegrinelli bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT pierreoliviercomby bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT bertillebonniaud bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT marcomidulla bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients AT romaricloffroy bleomycinforpercutaneoussclerotherapyofvenousandlymphaticmalformationsaretrospectivestudyofsafetyefficacyandmidtermoutcomesin26patients |